IQN Path free access to CBQAReadout.ca
IQN Path is pleased to announce and endorse two new CBQAReadout modules including VENTANA PD-L1 (SP142) Assay, NSCLC, atezolizumab (3 hours) and VENTANA PD-L1 (SP263) Assay, NSCLC, nivolumab (3 hours). VENTANA PD-L1 (SP142) Assay, triple negative breast cancer, atezolizumab and nab-paclitaxel (2 hours) module will be open on June 1st, 2020. We will update you regularly read more…
Proficiency testing CBQA Readout
An academic proficiency testing program for the assessment of pathologists’ and technologists’ accuracy of biomarker readout IQN Path is pleased announce and endorse CBQAReadout.com. CBQAReadout.com (www.cbqareadout.ca) is a new proficiency testing (PT) program for pathologists’ readouts. The primary focus of this new PT program are predictive immunohistochemistry biomarkers such as PD-L1. In the future, the read more…
SeraCare to Develop NGS Standards for Tumor Mutational Burden Monitoring
This article was originally published on http://www.clpmag.com/2019/04/seracare-develop-ngs-standards-tumor-mutational-burden-monitoring/ Under its agreement with IQN Path, SeraCare will develop, manufacture, and supply a range of highly characterized cell line genomic DNA and formalin-fixed, paraffin-embedded standards with confirmed low, mid, and high levels of mutational burden within their exome regions. Beginning in June 2019, the materials will be sent read more…
IQN Path Selects SeraCare Life Sciences for First-Ever Tumor Mutational Burden External Quality Assessment Program
International expert group focused on improving quality of clinical biomarker testing launching pilot TMB proficiency program in Spring 2019 MILFORD, Mass., WED. March 27, 2019 /PRNewswire/ — SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today their successful selection as a technology partner read more…
New article in the journal BMC Cancer
IQN Path has an article from the liquid biopsy working group published in the journal BMC Cancer entitled: “International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA” The full article can be found here at this link: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4694-x
Come and see IQN Path at the ECP 2018 Exhibition
IQN Path will again have a stand at the 30th European Congress of Pathology being held on 8th – 12th September 2018 in the Euskalduna Conference Centre in Bilbao, Spain. We will be using the stand to meet with both current IQN Path members and new potential members. We are Stand number 18 in Hall read more…
New IQN Path Board Announced
IQN Path Members Area
One of the benefits of being a member of IQN Path is that all member organisations have access to our secure member’s area on the IQN Path website. In this area we post all manner of papers including Governance documents and the Annual IQN Path report. Meeting summaries and agendas, both general meetings but also read more…